Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors

Zhang, Yong; Sun, Lingli; Li, Tao; Sun, Hui; Mao, Guo-Jia

doi:10.7314/apjcp.2014.15.17.7277

Cited by 3 publications

(3 citation statements)

References 46 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Currently, several researches reported that the toxicity of carboplatin-based treatment was relatively low and unapparent. [36,37] Therefore, it was speculated that gemcitabine was more likely to cause the toxic effects of the carboplatin + gemcitabine chemotherapy regimen. Besides, current researches still cannot reach agreement on the toxic effects of gemcitabine.…”

Section: Discussionmentioning

confidence: 99%

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

Sun

Yang

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

Section: Discussionmentioning

confidence: 99%

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

Sun

Yang

et al. 2017

Medicine

View full text Add to dashboard Cite

show abstract

“…PC is a relatively common first-line chemotherapy regimen. Carboplatin, a commonly used adjuvant with acceptable toxicities, has shown great efficacy in combination therapy [32]. Pacilitaxel promotes stable microtubule assembly by acting specifically at the beta-tubulin subunit N-terminus [33], impeding depolymerization and inhibiting cancer cell division [9].…”

Section: Discussionmentioning

confidence: 99%

A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer

et al. 2016

View full text Add to dashboard Cite

This study compared the short-term efficacies of different chemotherapy regimens in the treatment of advanced ovarian cancer (AOC) through pair-wise and network meta-analyses (NMA). Randomized controlled trials (RCTs) identified in a comprehensive online literature search met our inclusion criteria. Direct and indirect evidence was combined to compare odds ratios (OR) and surfaces under the cumulative ranking curves (SUCRA) across the different treatment regimens. Twelve eligible RCTs were finally included, involving eight regimens (Paclitaxel + Carboplatin [PC], Gemcitabine + Carboplatin [GC], Carboplatin, Pegylated Liposomal Doxorubicin + Carboplatin [PLD + Carboplatin], Paclitaxel, Paclitaxel + Carboplatin + Topotecan [PC + Topotecan], Paclitaxel + Carboplatin + Epirubicin [PC + Epirubicin] and Docetaxel + Carboplatin [DC]). The NMA results revealed that in terms of overall response rate (ORR) and disease control rate (DCR), PC (ORR: OR=2.59, 95%CI=1.20–6.22; DCR: OR=2.58, 95%CI=1.05–6.82) and GC (ORR: OR=2.08, 95%CI=1.08–4.37; DCR: OR=2.43, 95%CI=1.07–5.80) were more effective against AOC than Carboplatin alone. Similarly, PC (OR=0.21, 95%CI=0.05–0.69), GC (OR=0.31, 95%CI=0.09–0.90) and PLD + Carboplatin (OR=0.22, 95%CI=0.04–0.92) slowed disease progression better than Carboplatin alone. We also found that PC was more efficacious against AOC than Carboplatin or Paclitaxel single-agent chemotherapy. Combination chemotherapy is thus recommended for AOC, and should guide subsequent drug development and treatment strategies.

show abstract

“…The etiology of WT is unclear and may be related to mutations in genes that regulate normal embryonic development of the urogenital tract ( Stock et al, 2002 ; Fukuzawa and Reeve, 2007 ). Most patients have a palpable abdominal mass as the first symptom, and some patients may present with symptoms of hematuria, fever, urinary tract infection, varicocele, and anemia ( Zhang et al, 2014 ). Currently, WT is treated with a multidisciplinary combination of surgical, chemotherapy, radiotherapy, and targeted therapy, with an overall cure rate of approximately 90% ( Anvar et al, 2019 ; Palmisani et al, 2021 ; Pelosi et al, 2021 ).…”

Section: Roles and Significance Of Circrnas In Pediatric Malignant Solid Tumorsmentioning

confidence: 99%

Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors

Shen

Liu

et al. 2022

Front. Genet.

Self Cite

View full text Add to dashboard Cite

Circular RNAs (circRNAs) are non-coding RNAs with covalent closed-loop structures and are widely distributed in eukaryotes, conserved and stable as well as tissue-specific. Malignant solid tumors pose a serious health risk to children and are one of the leading causes of pediatric mortality. Studies have shown that circRNAs play an important regulatory role in the development of childhood malignant solid tumors, hence are potential biomarkers and therapeutic targets for tumors. This paper reviews the biological characteristics and functions of circRNAs as well as the research progress related to childhood malignant solid tumors.

show abstract

Clinical Study on Carboplatin for Treating Pediatric Patients with Wilms Tumors

Abstract: According to this background, we hypothesize that carboplatin originated regimen could be established as an optimal schedule for treating pediatric patients with WT.

Cited by 3 publications

References 46 publications

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer

A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer

Emerging Role and Mechanism of circRNAs in Pediatric Malignant Solid Tumors

Contact Info

Product

Resources

About